Santarus to Present Phase Rifamycin SV MMX III Data
October 04, 2013 at 07:08 AM EDT
Santarus (NASDAQ: SNTS ) today announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX® in patients with travelers' diarrhea will be featured in a poster presentation at IDWeek™ in San Francisco at the Moscone Center (Poster Hall C) from 12:30 p.m.
